Tuesday, March 31, 2009
ClearTrial, a provider of clinical trial software, appointed Michael Bruns as the company’s new chief operating officer. Bruns will oversee ClearTrial’s global operations and help further develop and implement the company’s growth strategy. Prior to joining ClearTrial, Bruns was director of the Technology Investment Banking Group at Robert W. Baird, a global investment banking firm.
Chinese contract research organization (CRO) WuXi Pharmatech reported an 87% increase in 2008 revenues compared with 2007, with net revenues for continuing operations of $253.5 million. Fourth-quarter 2008 net revenues from continuing operations increased 74% to $64.4 million compared with fourth quarter 2007. The CRO’s non-GAAP net income for 2008 was $58.3 million, up 31% from $44.6 million in 2007.
Dr. Michael McKelvey, CEO of
, a leading provider of centralized ECG and eClinical technology, ePRO, and other services to the biopharmaceutical, medical device, and related industries, discusses the benefits of electronic patient reported outcomes (ePRO) tools for assessing and monitoring suicidality in clinical drug trials.